期刊文献+

二甲双胍干预治疗葡萄糖耐量减低的疗效观察 被引量:1

下载PDF
导出
摘要 目的:探讨二甲双胍对葡萄糖耐量减低(IGT)患者干预治疗的临床疗效。方法:将48例IGT患者分成两组,治疗组和对照组各24例,两组均予一般治疗,治疗组加用二甲双胍,疗程12个月。结果:12个月后治疗组各项指标(空腹及餐后血糖、血脂、胰岛素敏感指数、体重指数、血压)与对照组比较,差异均有显著性(P<0.01)。结论:二甲双胍对IGT人群的干预治疗,不仅能够有效逆转IGT,降低2型糖尿病(T 2DM)的发生率,而且能够对IGT伴随的代谢紊乱因素进行积极处理。
作者 荣青峰
出处 《临床医药实践》 2008年第11期902-903,共2页 Proceeding of Clinical Medicine
  • 相关文献

参考文献4

二级参考文献33

  • 1谢军,邹洁宁,顾丽萍,黄伟.二甲双胍对糖耐量减低患者血压的影响[J].临床荟萃,2004,19(14):823-824. 被引量:4
  • 2Knowler WC, Barrett-Connor E, Fowler SE,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin [J]. N Engl J Med,2002,346(6):393-403.
  • 3Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program [ J ]. Diabetes Care,2003,26 (4) :977-980.
  • 4Scheen AJ,Letiexhe MR,Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance[ J]. Diabet Med, 1995,12( 11 ) :985-989.
  • 5Pan XR,Li GW,Hu YH,et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study [ J]. Diabetes Care, 1997,20 (4) : 537-544.
  • 6Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle amoug subjects with impaired glucose tolerance [ J ]. N Engl J Med, 2001,344 ( 18 ) : 1343-1350.
  • 7Rodriguez-Moctezuma JR, Robles-Lopez G, Lopez-Carmona JM, et al. Effects of metformin on the body composition in subjects with risk factors fbr type 2 diabetes[ J]. Diabetes Obes Metab,2005,7 (2) :189- 192.
  • 8Yusuf S;Gerstein H;Hoogwert B.Ramipril and the Development of Diabetes,2001.
  • 9Martens FM;Visseren FL;Lemay J.Metabolic and additional vascular effects of thiazolidinediones[J],2002(10).
  • 10Rubin RR;Fujimoto WY;Marrero DG.The diabetes prevention program: recruitment methods and results[J],2002(02).

共引文献25

同被引文献24

  • 1Yusuf S;Gerstein H;Hoogwert B.Ramipril and the Development of Diabetes,2001.
  • 2Martens FM;Visseren FL;Lemay J.Metabolic and additional vascular effects of thiazolidinediones[J],2002(10).
  • 3Rubin RR;Fujimoto WY;Marrero DG.The diabetes prevention program: recruitment methods and results[J],2002(02).
  • 4Lindholm LH;Ibsen H;Borch-Johnsen K.Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study[J],2002(09).
  • 5Anon.Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality inhypertension: the captopril prevention project (CAPP) randomized trial,1999(06).
  • 6Saloranta C;Guitard C;Pecher E.Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population[J],2002(12).
  • 7Kentrup H;Bongers H;Spengler M.Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance[J],1999.
  • 8Buchanan TA;Xiang AH;Peters RK.Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women[J],2002(09).
  • 9Knowler WC;Barrett-Connor E;Fowler SE.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J],2002(06).
  • 10Tuomilehto J;Lindstrom J;Eriksson JG.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J],2001(18).

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部